Search

Hydrocortisone acetate

Durvalumab

Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. … [L12624] It is additionally approved in Canada under the same name (Imfinzi) for similar indications, as well as the treatment of patients with locally advanced or metastatic urothelial carcinoma.

Terpin hydrate

It is derived from sources such as turpentine, oregano, thyme and eucalyptus. … Elixirs of terpin hydrate are still available to patients as prescription medications to be prepared by specialty compounding pharmacies.

Colistin

It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes.

Grazoprevir

Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. … Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

Amifostine

A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.

Triflupromazine

A phenothiazine used as an antipsychotic agent and as an antiemetic.

Ammonia

It is a colorless gas with a pungent smell, and become NH4, or ammonium ion, when in water. … Although ammonia is used as a food additive in the anhydrous form and serves as a starting material in pharmaceutical and commercial products, it is caustic and hazardous when concentrated.

Gimeracil

The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells. … This allows higher concentrations of 5-FU to be achieved with a lower dose of tegafur, thereby also reducing toxic side effects.

Dexrazoxane

It appears to inhibit formation of a toxic iron-anthracycline complex. … [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.